Depression and ischemic heart disease: Overview of the evidence and treatment implications

Current Psychiatry Reports

Volumn 5, Issue 1, 2003, Pages 47-54

  Jiang, Wei ^a   Blumenthal, James A ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; AMFEBUTAMONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYTOCHROME P450; FLUOXETINE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; PLACEBO; SEROTONIN 2A ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; WARFARIN;

ADRENERGIC SYSTEM; ANHEDONIA; BECK DEPRESSION INVENTORY; BEHAVIOR THERAPY; BODY WEIGHT DISORDER; CARDIOVASCULAR DISEASE; CHOLINERGIC SYSTEM; COGNITIVE THERAPY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; ELECTROCONVULSIVE THERAPY; HEART INFARCTION; HEART MUSCLE CONDUCTION DISTURBANCE; HOSPITALIZATION; HUMAN; HYPERTENSION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INTERVIEW; ISCHEMIC HEART DISEASE; LONELINESS; MORTALITY; ORTHOSTATIC HYPOTENSION; PROGNOSIS; PSYCHOSOMATIC DISORDER; PSYCHOTHERAPY; QUESTIONNAIRE; RATING SCALE; REVIEW; RISK FACTOR; SOCIOTHERAPY; TACHYCARDIA; WEIGHT GAIN; ADULT; AGED; FEMALE; HEART MUSCLE ISCHEMIA; MALE; MIDDLE AGED; PSYCHOLOGICAL ASPECT;

ADULT; AGED; AGED, 80 AND OVER; DEPRESSIVE DISORDER; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA;

EID: 0642284396     PISSN: 15233812     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11920-003-0009-1     Document Type: Review

References (70)

1. Hallstrom T, Lapidus L, Bengtsson C, et al.: Psychosocial factors and risk of ischaemic heart disease and death in women: a twelve-year follow-up of participants in the population study of women in Gothenburg, Sweden. J Psychosom Res 1986, 30: 451-459.
2. Carney RM, Rich MW, Freedland KE, et al.: Major depressive disorder predicts cardiac events in patients with coronary artery disease. Psychosom Med 1988, 50:627-633.
3. Schleifer SJ, Macari-Hinson MM, Coyle DA, et al.: The nature and course of depression following myocardial infarction. Arch Intern Med 1989, 149:1785-1789.
4. Anda R, Williamson D, Jones D, et al.: Depressed affect, hopelessness, and the risk of ischemic heart disease in a cohort of US adults. Epidemiology 1993, 4:285-294.
5. Aromaa A, Raitasalo R, Reunanen A, et al.: Depression and cardiovascular diseases. Acta Psychiatr Scand Suppl 1994, 377:77-82.
6. Everson SA, Goldberg DE, Kaplan GA, et al.: Hopelessness and risk of mortality and incidence of myocardial infarction and cancer. Psychosom Med 1996, 58:113-121.
7. Wassertheil-Smoller S, Applegate WB, Berge K, et al.: Change in depression as a precursor of cardiovascular events. SHEP Cooperative Research Group (Systolic Hypertension in the Elderly Project). Arch Intern Med 1996, 156:553-561.
8. Pratt LA, Ford DE, Crum RM, et al.: Depression, psychotropic medication, and risk of myocardial infarction: prospective data from the Baltimore ECA follow-up. Circulation 1996, 94:3123-3129.
9. Mendes de Leon CF, Krumholz HM, Seeman TS, et al.: Depression and risk of coronary heart disease in elderly men and women: New Haven EPESE, 1982-1991. Established Populations for the Epidemiologic Studies of the Elderly. Arch Intern Med 1998, 158:2341-2348.
10. Ariyo AA, Haan M, Tangen CM, et al.: Depressive symptoms and risks of coronary heart disease and mortality in elderly Americans. Cardiovascular Health Study Collaborative Research Group. Circulation 2000, 102:1773-1779.
11. Ferketich AK, Schwartzbaum JA, Frid DJ, Moeschberger ML: Depression as an antecedent to heart disease among women and men in the NHANES I study. National Health and Nutrition Examination Survey. Arch Intern Med 2000, 160:1261-1268.
12. Penninx BW, Beekman AT, Honig A, et al.: Depression and cardiac mortality: results from a community-based longitudinal study. Arch Gen Psychiatry 2001, 58:221-227.
13. Frasure-Smith N, Lesperance F, Talajic M: Depression following myocardial infarction: impact on 6-month survival. JAMA 1993, 270:1819-1825.
14. Frasure-Smith N, Lesperance F, Talajic M: Depression and 18-month prognosis after myocardial infarction. Circulation 1995, 91:999-1005.
15. Barefoot JC, Schroll M: Symptoms of depression, acute myocardial infarction, and total mortality in a community sample. Circulation 1996, 93:1976-1980.
16. Lesperance F, Frasure-Smith N, Juneau M, Theroux P: Depression and 1-year prognosis in unstable angina. Arch Intern Med 2000, 160:1354-1360.
17. Irvine J, Basinski A, Baker B, et al.: Depression and risk of sudden cardiac death after acute myocardial infarction: testing for the confounding effects of fatigue. Psychosom Med 1999, 61:729-737.
18. Weeke A, Juel K, Vaeth M: Cardiovascular death and manic-depressive psychosis. J Affective Dis 1987, 13:287-292.
19. Appels A, Mulder P: Excess fatigue as a precursor of myocardial infarction. Eur Heart J 1988, 9:758-764.
20. Barefoot JC, Helms MJ, Mark DB, et al.: Depression and long-term mortality risk in patients with coronary artery disease. Am J Cardiol 1996, 78:613-617.
21. Ford DE, Mead LA, Chang PP, et al.: Depression is a risk factor for coronary artery disease in men: the Precursors study. Arch Intern Med 1998, 158:1422-1426.
22. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, edn 4. Washington, DC: American Psychiatric Association Press; 1994.
23. Shapiro PA, Lesperance F, Frasure-Smith N, et al.: An open-label preliminary trial of sertraline for treatment of major depression after acute myocardial infarction (the SADHAT Trial). Am Heart J 1999, 137:1100-1106.
24. Frasure-Smith N, Lesperance F, Juneau M, et al.: Gender, depression, and one-year prognosis after myocardial infarction [see comments]. Psychosom Med 1999, 61:26-37.
25. Lane D, Carroll D, Ring C, et al.: Mortality and quality of life after myocardial infarction: effects of depression and anxiety. Psychosom Med 2001, 63:221-230.
26. Ladwig KH, Roll G, Breithardt G, et al.: Post-infarction depression and incomplete recovery 6 months after acute myocardial infarction [see comments]. Lancet 1994, 343:20-23.
27. Stern MJ, Pascale L, Ackerman A: Life adjustment postmyocardial infarction: determining predictive variables. Arch Intern Med 1977, 137:1680-1685.
28. Ahern DK, Gorkin L, Anderson JL, et al.: Biobehavioral variables and mortality or cardiac arrest in the Cardiac Arrhythmia Pilot Study (CAPS). Am J Cardiol 1990, 66:59-62.
29. Denollet J, Brutsaert DL: Personality, disease severity, and the risk of long-term cardiac events in patients with a decreased ejection fraction after myocardial infarction. Circulation 1998, 97:167-173.
30. Mayou RA, Gill D, Thompson DR, et al.: Depression and anxiety as predictors of outcome after myocardial infarction. Psychosom Med 2000, 62:212-219.
31. Jiang W, Alexander J, Christopher E, et al.: Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch Intern Med 2001,161:1849-1856.
32. Musselman DL, Evans DL, Nemeroff CB: The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch Gen Psychiatry 1998, 55:580-592.
33. Pariante CM, Miller AH: Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry 2001, 49:391-404.
34. Malhotra S, Tesar GE, Franco K: The relationship between depression and cardiovascular disorders. Curr Psychiatry Rep 2000, 2:241-246.
35. Roy A, Pickar D, Dejong J, et al.: Norepinephrine and its metabolites in cerebrospinal fluid, plasma and urine: relationship to hypothalamic-pituitary-adrenal axis function in depression. Arch Gen Psychiatry 1988, 45:849-857.
36. Roy A, Guthrie S, Pickar D, Linnoila M: Plasma norepinephrine responses to cold challenge in depressed patients and normal controls. Psychiatry Res 1987, 21:161-168.
37. Anfossi G, Trovati M: Role of catecholaamines in platelet function: pathophysiological and clinical significance. Eur J Clin Invest 1996, 26:353-370.
38. American College of Cardiology Cardiovascular Technology Assessment Committee: Heart rate variability for risk stratification of life-threatening arrhythmias. J Am Coll Cardiol 1993, 22:948-950.
39. Carney RM, Saunders RD, Freedland KE, et al.: Association of depression with reduced heart rate variability in coronary artery disease. Am J Cardiol 1995, 76:562-564.
40. Musselman DL, Tomer A, Manatunga AK, et al.: Exaggerated platelet reactivity in major depression. Am J Psychiatry 1996, 153:1313-1317.
41. Laghrissi-Thode F, Wagner WR, Pollock BG, et al.: Elevated platelet factor 4 and beta-thromboglobulin plasma levels in depressed patients with ischemic heart disease. Biol Psychiatry 1997, 42:290-295.
42. Maes M, Ombelet W, De Jongh R, et al.: The inflammatory response following delivery is amplified in women who previously suffered from major depression, suggesting that major depression is accompanied by a sensitization of the inflammatory response system. J Affective Disorders 2001, 63:85-92.
43. Song C, Lin A, Bonaccorso S, et al.: The inflammatory response system and the availability of plasma tryptophan in patients with primary sleep disorders and major depression. J Affective Disorders 1998, 49:211-219.
44. Libby P: What have we learned about the biology of atherosclerosis? The role of inflammation. Am J Cardiol 2001, 88:31-61.
45. Siegler HC, Blumenthal JA, Barefoot JC, et al.: Personality factors differentially predict exercise behavior in men and women. Womens Health 1997, 3:61-70.
46. Adler NE, Boyce T, Chesney MA, et al.: Socioeconomic status and health: the challenge of the gradient. Am J Psychol 1994, 49:15-24.
47. Horsten M, Mittleman MA, Wamala SP, et al.: Depressive symptoms and lack of social integration in relation to prognosis of IHD in middle-aged women. The Stockholm Female Coronary Risk Study. Eur Heart J 2000, 21:1072-1080.
48. Krishnan KR, George LK, Pieper CF, et al.: Depression and social support in elderly patients with cardiac disease. Am Heart J 1998, 136:491-495.
49. Anda RF, Williamson DF, Escobedo LG, et al.: Depression and the dynamics of smoking: a national perspective. JAMA 1990, 264:1541-1545.
50. Carney RM, Freedland KE, Eisen SA, et al.: Major depression and medication adherence in elderly patients with coronary artery disease. Health Psychol 1995, 14:88-90.
51. Ziegelstein RC, Fauerbach JA, Stevens SS, et al.: Patients with depression are less likely to follow recommendations to reduce cardiac risk during recovery from a myocardial infarction. Arch Intern Med 2000, 160:1818-1823.
52. Sheline YI, Freedland KE, Carney RM: How safe are serotonin reuptake inhibitors for depression in patients with coronary heart disease? Am J Med 1997, 102:54-59.
53. Frank E, Kupfer DJ, Perel JM, et al.: Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990, 47:1093-1099.
54. Veith RC, Lewis N, Linares OA, et al.: Sympathetic nervous system activity in major depression: basal and desipramine-induced alterations in plasma norepinephrine kinetics. Arch Gen Psychiatry 1994, 51:411-422.
55. Nelson JC, Kennedy JS, Pollock BG, et al.: Treatment of major depression with amitriptyline and paroxetine in patients with ischemic heart disease. Am J Psychiatry 1999, 156:1024-1028.
56. Epstein AE, Hallstrom AP, Rogers WJ, et al.: Mortality following ventricular arrhythmia suppression by encainide, flecainide, and moricizine after myocardial infarction. JAMA 1993, 270:2451-2455.
57. CAST Investigators: Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989, 321:406-1421.
58. Glassman AH, Bigger JT Jr, Giardina EV, et al.: Clinical characteristics of imipramine-induced orthostatic hypotension. Lancet 1979, 1:468-725.
59. Roose SP, Glassman AH, Giardina EGV, et al.: Tricyclic antidepressants in depressed patients with cardiac conduction disease. Arch Gen Psychiatry 1987, 44:273-256.
60. Strik JJMH, Honig A, Lousberg R, et al.: Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial. Psychosom Med 2000, 62:783-789.
61. Roose SP, Laghrissi-Thode F, Kennedy JS, et al.: Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA 1998, 279:287-291.
62. Glassman AH, O'Connor CM, Califf RM, et al.: Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002, 288:701-709.
63. Hersen M, Bellack AS, Himmelhoch JM, Thase ME: Effects of social skill training, amitriptyline, and psychotherapy in unipolar depressed women. Behav Ther 1984, 15:21-40.
64. Lewinsohn PM, Gotlib IH: Behavioral theory and treatment of depression. In Handbook of Depression. Edited by Becker EE, Leber WR. New York: Guilford Press; 1995:352-375.
65. Beck JS: Why distinguish between cognitive therapy and cognitive behavioral therapy. Cognitive Ther Today 2001, 6:1-4.
66. Evans MD, Hollon SD, DeRubeis RJ, et al.: Differential relapse following cognitive therapy and pharmacotherapy for depression. Arch Gen Psychiatry 1992, 49:802-808.
67. Elkin I, Parloff MB, Hadley SW, Autry JH: NIMH treatment of depression collaborative research program: Background and research plan. Arch Gen Psychiatry 1985, 42:305-316.
68. Keller MB, McCullough JP, Klein DN, et al.: A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med 2000, 342:1462-1470.
69. The ENRICHD Investigators: Enhancing recovery in coronary heart disease patients (ENRICHD): study design and methods. Am Heart J 2001, 139:1-9.
70. Rayburn BK: Electroconvulsive therapy in patients with heart failure or valvular heart disease. Convuls Ther 1997, 13:145-156.